NOEVIR HOLDINGS CO., LTD. Noevir Holdings Co., Ltd.
Results for the First Half of Fiscal 2024
(October 1, 2023 - March 31, 2024)
May 16, 2024
Noevir Holdings Co., Ltd.
Ikkou Yoshida, Managing Director
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
Company Overview
Noevir Holdings Co., Ltd. Tokyo Stock Exchange, Prime Market Ticker: 4928
Date of Establishment | March 22, 2011 (Noevir Co., Ltd. was founded in April 1964.) |
Paid-in Capital | ¥7,319 million |
Consolidated Subsidiaries | 13 subsidiaries (6 domestic / 7 international) |
Employees | 1,368 (Consolidated) (As of September 30, 2023) |
Number of Shareholders | 19,663 (As of March 31, 2024) |
Outstanding Shares | 34,156 thousand shares |
Market Capitalization | ¥181.030 billion (May 15, 2024 @ ¥5,300) |
Line of Business |
Cosmetics | Pharmaceuticals & Health Food | ||
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved. |
Apparel
business Aviation- related business
Other
1. Results for the First Half of Fiscal 2024
2. The First Half of Fiscal 2024 Segment-Based Highlights
3. Medium-term Management Plan
4. Forecasts and Initiatives
for the Second Half of Fiscal 2024
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
The First Half of Fiscal 2024
Consolidated Results Summary
Increased sales and profits vs. actual results year on year
1st half of | Year-on-year | |
fiscal 2024 | change | |
Net sales | 31.6 billion yen | +2.4 |
Operating income | 6.1 billion yen | +7.2 |
Operating income margin | 19.5 | +0.9pt |
➢ Factors increasing sales and profits | Operating income | |
(1) Self-selection cosmetics performed strongly | margin | |
19.5 | ||
(2) SG&A expenses were streamlined | ||
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
The First Half of Fiscal 2024 Highlights
Net sales 31.6 billion yen (+2.4% year-on-year), operating income 6.1 billion yen (+7.2%),
ordinary income 6.2 billion yen (+7.5%), net income attributable to owners of the parent 2.5 billion yen (-2.8%)
1st half ended | 1st half ended | Year-on-year change |
March 31, 2024 | March 31, 2023 | |
Millions of yen | Millions of yen | Millions of yen |
Net sales
31,625 | 30,896 | 729 | 2.4 |
Cost of sales | 9,935 | 9,629 | 306 | 3.2 | ||
Gross profit | 21,689 | 21,267 | 422 | 2.0 | ||
SG&A | 15,524 | 15,517 | 7 | 0.0 | ||
Operating income | 6,165 | 5,750 | 415 | 7.2 | ||
Non-operating income (expenses) | 80 | 59 | 21 | 36.5 | ||
Ordinary income | 6,246 | 5,809 | 436 | 7.5 | ||
Extraordinary income (loss) | 13 | (1) | 15 | |||
Income before income taxes | 6,259 | 5,807 | 451 | 7.8 | ||
Income taxes | 3,661 | 3,135 | 526 | 16.8 | ||
Net income attributable to owners of the parent | 2,597 | 2,672 | (74) | (2.8) | ||
Cost of sales ratio (%) | 31.4 | 31.2 | 0.2pt | |||
Operating income margin (%) | 19.5 | 18.6 | 0.9pt | |||
Ordinary income margin (%) | 19.8 | 18.8 | 0.9pt | |||
Net income attributable to owners of the parent margin (%) | 8.2 | 8.6 | (0.4pt) | |||
SG&A ratio (%) | 49.1 | 50.2 | (1.1pt) | |||
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
Operating Income Margin
19.6% | 20.2% | 19.5% |
18.3%
16.7%17.6%
15.4% | 15.5% | |
14.6% | 15.1% | |
FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | 1st half of |
fiscal 2024 | ||||||||||
Continued to maintain a high operating income margin in 1H FY2024
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
The First Half of Fiscal 2024
Reasons for Change in Operating Income
+422 | +24 | |||
Increasein gross profit | salestodue increase | -31 | ||
5,750 | Increase in A&P | Decreasein sundry expenses | ||
1st half of | Increase in operating income of 415 million yen |
fiscal 2023 |
(Millions of yen)
Factors increasing profit Factors decreasing profit
6,165
1st half of fiscal 2024
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
Monthly Net Sales in the
Cosmetics Segment Year on Year
Fiscal 2024
Oct. | Nov. | Dec. | Jan. | Feb. | Mar. | Apr. | May | Jun. | Jul. | Aug. Sep. | Oct. | Nov. | Dec. | Jan. | Feb. Mar. |
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
- Results for the First Half of Fiscal 2024
- The First Half of Fiscal 2024 Segment-Based Highlights
- Medium-termManagement Plan
- Forecasts and Initiatives
for the Second Half of Fiscal 2024
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
The First Half of Fiscal 2024 Segment-Based Highlights
1st half ended | 1st half ended | Year-on-year change |
March 31, 2024 | March 31, 2023 | |
Millions of yen | Millions of yen | Millions of yen |
Cosmetics |
Net sales | 25,103 | 24,091 | 1,011 | 4.2 |
Segment income | 6,507 | 6,174 | 333 | 5.4 |
Pharmaceuticals & | ||||
Health Food | ||||
Net sales | 5,498 | 5,579 | (81) | (1.5) |
Segment income | 683 | 542 | 141 | 26.1 |
Other | ||||
Net sales | 1,024 | 1,225 | (201) | (16.4) |
Segment income | 150 | 164 | (14) | (8.8) |
Consolidated net | 31,625 | 30,896 | 729 | 2.4 |
sales | ||||
Other
Pharmaceuticals &3.2%
Health Food
17.4%
Net sales
31,625
million yen
Cosmetics
79.4%
Composition of net sales in the first half of fiscal 2024
Cosmetics
Pharmaceuticals &
Health Food
Other
Sales and profits increased year on year
Sales decreased and profits increased year on year
Sales and profits decreased year on year
Sales and profit increased due to firm sales of self-selection cosmetics
Profit increased due to improved cost efficiency, despite decreased sales of functional drinks
Sales decreased in aviation-related business
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Noevir Holdings Co. Ltd. published this content on 16 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 May 2024 00:05:01 UTC.
